Patent Expiration to Partnership Target: What 9 Deals Show
Keytruda sold $31.68 billion in 2025. That was 48.7% of Merck’s total sales of $65.01 billion. [1] Merck lists the
Patent Expiration to Partnership Target: What 9 Deals Show Read Post »
Keytruda sold $31.68 billion in 2025. That was 48.7% of Merck’s total sales of $65.01 billion. [1] Merck lists the
Patent Expiration to Partnership Target: What 9 Deals Show Read Post »
FDA listed 91 first generic drug approvals for 2025 [2]. Each one passed through a chain of checks that a
Drug Patent Expiration: The Hidden Work Before a Generic Launch Read Post »
The European Medicines Agency authorized Eliquis (apixaban) on 18 May 2011 [10]. The compound patent behind it, EP 1 427
Global Patent Expiration Dates: One Drug, Many Clocks Read Post »
The main US combination patent for Entresto expired on July 15, 2025, with its pediatric exclusivity. [1] Novartis’s own 2023
Patent Expiration Isn’t Generic Entry: How to Find the Date That Counts Read Post »
In 2024, the Intellectual Property Office of the Philippines (IPOPHL) granted 2,063 patents. Non-residents received 1,958 of them. That is
The Philippines Pharma Opportunity Map: What Patent Expirations Can and Cannot Tell You Read Post »
FDA listed 91 first generic drug approvals for 2025. [1] Evaluate reports that more than $300 billion in prescription drug
Merck says U.S. Patent No. 7,326,708 covers the sitagliptin salt in Januvia and expires on November 24, 2026 [1]. Settlements
Patent Expiration Is a Trigger. What You Really Need Is the Opportunity Behind It. Read Post »
Humira had U.S. net revenues of $21.237 billion in 2022. [1] It made up about 37% of AbbVie’s total net
Loss of Exclusivity vs. Patent Expiration: Track the Date That Moves Revenue Read Post »
ANDROGEL (testosterone) Besins hlthcare Patent: 8,466,137 Expiration: Oct 12, 2026 See More … For more information on how DrugPatentWatch can
Drug Patent Expirations for the Week of October 11, 2026 Read Post »
Sign in or create a free account to read this DrugPatentWatch article